drugset / Trial / NCT07566195
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
Phase 3
Recruiting
60 enrolled
AstraZeneca
Clinact, Multihealth Group · collabContract Research Organization · collab
NaParallel-groupOpen-labelTreatment
Summary
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations. Eligible participants must have completed one of the predecessor studies.
Timeline
- Start
- 2026-05-05
- Primary completion
- 2028-12-29
- Completion
- 2028-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tozorakimab | Monoclonal antibody | — | Subcutaneous |